Literature DB >> 26500230

Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?

Zofia Piotrowska1, Lecia V Sequist2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26500230      PMCID： PMC4718438          DOI： 10.1634/theoncologist.2015-0370

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  9 in total

1.  Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.

Authors:  Peter C Lo; Suzanne E Dahlberg; Mizuki Nishino; Bruce E Johnson; Lecia V Sequist; David M Jackman; Pasi A Jänne; Geoffrey R Oxnard
Journal:  Cancer       Date:  2015-04-15       Impact factor: 6.860

2.  Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

Authors:  Zofia Piotrowska; Matthew J Niederst; Chris A Karlovich; Heather A Wakelee; Joel W Neal; Mari Mino-Kenudson; Linnea Fulton; Aaron N Hata; Elizabeth L Lockerman; Anuj Kalsy; Subba Digumarthy; Alona Muzikansky; Mitch Raponi; Angel R Garcia; Hillary E Mulvey; Melissa K Parks; Richard H DiCecca; Dora Dias-Santagata; A John Iafrate; Alice T Shaw; Andrew R Allen; Jeffrey A Engelman; Lecia V Sequist
Journal:  Cancer Discov       Date:  2015-05-01       Impact factor: 39.397

3.  Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

Authors:  Jean-Charles Soria; Yi-Long Wu; Kazuhiko Nakagawa; Sang-We Kim; Jin-Ji Yang; Myung-Ju Ahn; Jie Wang; James Chih-Hsin Yang; You Lu; Shinji Atagi; Santiago Ponce; Dae Ho Lee; Yunpeng Liu; Kiyotaka Yoh; Jian-Ying Zhou; Xiaojin Shi; Alan Webster; Haiyi Jiang; Tony S K Mok
Journal:  Lancet Oncol       Date:  2015-07-06       Impact factor: 41.316

4.  Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.

Authors:  Juliann Chmielecki; Jasmine Foo; Geoffrey R Oxnard; Katherine Hutchinson; Kadoaki Ohashi; Romel Somwar; Lu Wang; Katherine R Amato; Maria Arcila; Martin L Sos; Nicholas D Socci; Agnes Viale; Elisa de Stanchina; Michelle S Ginsberg; Roman K Thomas; Mark G Kris; Akira Inoue; Marc Ladanyi; Vincent A Miller; Franziska Michor; William Pao
Journal:  Sci Transl Med       Date:  2011-07-06       Impact factor: 17.956

5.  Rociletinib in EGFR-mutated non-small-cell lung cancer.

Authors:  Lecia V Sequist; Jean-Charles Soria; Jonathan W Goldman; Heather A Wakelee; Shirish M Gadgeel; Andrea Varga; Vassiliki Papadimitrakopoulou; Benjamin J Solomon; Geoffrey R Oxnard; Rafal Dziadziuszko; Dara L Aisner; Robert C Doebele; Cathy Galasso; Edward B Garon; Rebecca S Heist; Jennifer Logan; Joel W Neal; Melody A Mendenhall; Suzanne Nichols; Zofia Piotrowska; Antoinette J Wozniak; Mitch Raponi; Chris A Karlovich; Sarah Jaw-Tsai; Jeffrey Isaacson; Darrin Despain; Shannon L Matheny; Lindsey Rolfe; Andrew R Allen; D Ross Camidge
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

6.  Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

Authors:  Jamie E Chaft; Geoffrey R Oxnard; Camelia S Sima; Mark G Kris; Vincent A Miller; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2011-08-19       Impact factor: 12.531

7.  Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.

Authors:  Sarah B Goldberg; Geoffrey R Oxnard; Subba Digumarthy; Alona Muzikansky; David M Jackman; Inga T Lennes; Lecia V Sequist
Journal:  Oncologist       Date:  2013-09-26

8.  Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.

Authors:  Balazs Halmos; Nathan A Pennell; Pingfu Fu; Shumaila Saad; Shirish Gadgeel; Gregory A Otterson; Tarek Mekhail; Michael Snell; J Philip Kuebler; Neelesh Sharma; Afshin Dowlati
Journal:  Oncologist       Date:  2015-08-25

9.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Authors:  Pasi A Jänne; James Chih-Hsin Yang; Dong-Wan Kim; David Planchard; Yuichiro Ohe; Suresh S Ramalingam; Myung-Ju Ahn; Sang-We Kim; Wu-Chou Su; Leora Horn; Daniel Haggstrom; Enriqueta Felip; Joo-Hang Kim; Paul Frewer; Mireille Cantarini; Kathryn H Brown; Paul A Dickinson; Serban Ghiorghiu; Malcolm Ranson
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245
  9 in total
  1 in total

1.  Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

Authors:  Corey A Carter; Bryan Oronsky; Scott Caroen; Jan Scicinski; Pedro Cabrales; Aiste Degesys; Christina Brzezniak
Journal:  Respir Med Case Rep       Date:  2016-04-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.